Pharminent

China’s NMPA approves Bio-Thera’s BAT2506 for arthritis indications

China’s NMPA has granted marketing authorization to Bio-Thera Solutions’ BAT2506 for the treatment of ankylosing spondylitis and rheumatoid arthritis.

Novartis’ pelacarsen cardiovascular outcomes trial data released

Novartis has revealed data from its cardiovascular outcomes trial of the Lp(a)-targeting drug pelacarsen, which failed, according to Pharmaphorum. Cardiologists were reported to be puzzled by the results.

Nkarta reports first human data for NK cell therapy in autoimmune disease

Nkarta will present initial clinical data for its natural killer cell therapy in myositis and systemic sclerosis at the American College of Rheumatology annual meeting in Orlando this week, showing safety and signs of efficacy.

argenx to buy Unnatural Products in deal worth up to $1.15B

argenx has agreed to acquire macrocyclic peptide drug developer Unnatural Products for $550 million upfront, in a deal worth up to $1.15 billion. It is argenx’s second acquisition of the year.

Network Bio and Duke University partner on AI disease models

Network Bio has entered a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.